141 related articles for article (PubMed ID: 30723040)
21. Progression of Cabozantinib-Related Osteonecrosis Mimicking Metastases on Bone Scan.
Xu G; Lu Y
Clin Nucl Med; 2021 Jul; 46(7):592-594. PubMed ID: 33577198
[TBL] [Abstract][Full Text] [Related]
22. Asymptomatic stroke is an underestimated side effect of cabozantinib.
Bronnimann C; Sibon I; Ravaud A; Gross-Goupil M
Rev Neurol (Paris); 2019 Jun; 175(6):409-410. PubMed ID: 31056194
[No Abstract] [Full Text] [Related]
23. Reversible Cabozantinib-Induced Cardiomyopathy.
Alhussein M; Hotte SJ; Leong DP
Can J Cardiol; 2019 Apr; 35(4):544.e1-544.e2. PubMed ID: 30935646
[TBL] [Abstract][Full Text] [Related]
24. Kidney cancer: CheckMate for advanced-stage ccRCC? Nivolumab and cabozantinib aMETEORate poor survival.
Thoma C
Nat Rev Clin Oncol; 2015 Nov; 12(11):621. PubMed ID: 26462125
[No Abstract] [Full Text] [Related]
25. CheckMate for advanced-stage ccRCC? Nivolumab and cabozantinib aMETEORate poor survival.
Thoma C
Nat Rev Urol; 2015 Dec; 12(12):651. PubMed ID: 26458750
[No Abstract] [Full Text] [Related]
26. Combination of cabozantinib and immune checkpoint inhibitors in advanced renal cell carcinoma: update from the European Society for Medical Oncology 2020.
Sarkis J; Khalil N; Alkassis M
Future Oncol; 2021 Mar; 17(9):991-992. PubMed ID: 33533650
[No Abstract] [Full Text] [Related]
27. Cabozantinib Approved for Renal Cell Carcinoma.
Cancer Discov; 2016 Jun; 6(6):OF3. PubMed ID: 27150533
[TBL] [Abstract][Full Text] [Related]
28. First case of hemophagocytic lymphohistiocytosis secondary to cabozantinib with checkpoint inhibitors.
Azari AE; Stratton R; Singh A
Rheumatology (Oxford); 2021 May; 60(5):e167-e168. PubMed ID: 33280022
[No Abstract] [Full Text] [Related]
29. Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Stukalin I; Wells JC; Graham J; Yuasa T; Beuselinck B; Kollmansberger C; Ernst DS; Agarwal N; Le T; Donskov F; Hansen AR; Bjarnason GA; Srinivas S; Wood LA; Alva AS; Kanesvaran R; Fu SYF; Davis ID; Choueiri TK; Heng DYC
Curr Oncol; 2019 Apr; 26(2):e175-e179. PubMed ID: 31043824
[TBL] [Abstract][Full Text] [Related]
30. Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer.
Di Nunno V; Cimadamore A; Santoni M; Scarpelli M; Fiorentino M; Ciccarese C; Iacovelli R; Cheng L; Lopez-Beltran A; Massari F; Montironi R
Future Oncol; 2018 Oct; 14(25):2559-2564. PubMed ID: 30141348
[No Abstract] [Full Text] [Related]
31. An overview of the clinical use of cabozantinib in the treatment of advanced non-clear-cell renal cell carcinoma (NCCRCC).
D'Angelo A; Bagby S; Di Pierro G; Chirra M; Nobili S; Mini E; Villari D; Roviello G
Crit Rev Oncol Hematol; 2020 May; 149():102921. PubMed ID: 32172222
[TBL] [Abstract][Full Text] [Related]
32. FDA Approved Uses of Cabozantinib.
Leavitt J; Copur MS
Oncology (Williston Park); 2019 Sep; 33(9):. PubMed ID: 31571185
[No Abstract] [Full Text] [Related]
33. A Drug Interaction Between Cabozantinib and Warfarin in a Patient With Renal Cell Carcinoma.
Foxx-Lupo WT; Sing S; Alwan L; Tykodi SS
Clin Genitourin Cancer; 2016 Feb; 14(1):e119-21. PubMed ID: 26549824
[No Abstract] [Full Text] [Related]
34. Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program.
Procopio G; Prisciandaro M; Iacovelli R; Cortesi E; Fornarini G; Facchini G; Cartenì G; Sabbatini R; Del Bene G; Galli L; Caserta C; Multari AG; Bregni M; Massari F; Buti S; De Giorgi U; Zustovich F; Milella M; Calabrò F; Mancini ML; Tortora G; Vernieri C; Santini D; Sorarù M; Ricotta R; Masini C; Tucci M; Fedeli SL; Ortega C; Mecozzi A; Ratta R; Sternberg CN; Verzoni E
Clin Genitourin Cancer; 2018 Aug; 16(4):e945-e951. PubMed ID: 29753637
[TBL] [Abstract][Full Text] [Related]
35. Real-world Experience of Cabozantinib as Second- or Subsequent Line Treatment in Patients With Metastatic Renal Cell Carcinoma: Data From the Polish Managed Access Program.
Bodnar L; Kopczyńska A; Żołnierek J; Wieczorek-Rutkowska M; Chrom P; Tomczak P
Clin Genitourin Cancer; 2019 Jun; 17(3):e556-e564. PubMed ID: 30987807
[TBL] [Abstract][Full Text] [Related]
36. Cabozantinib: a new first-line option for papillary renal cell carcinoma?
Borchiellini D; Barthélémy P
Lancet; 2021 Feb; 397(10275):645-647. PubMed ID: 33592177
[No Abstract] [Full Text] [Related]
37. Clinical efficacy of cabozantinib in two pediatric patients with recurrent renal cell carcinoma.
Wedekind MF; Ranalli M; Shah N
Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28417541
[TBL] [Abstract][Full Text] [Related]
38. Treatment of Cabozantinib-Related Palmar-Plantar Erythrodysesthesia With Topical Sildenafil, Diclofenac, and Gabapentin Cream: A Case Report.
Thai KJ; Ralph C; England D
JCO Oncol Pract; 2020 Mar; 16(3):135-136. PubMed ID: 31721626
[No Abstract] [Full Text] [Related]
39. Cabozantinib: A Review in Advanced Renal Cell Carcinoma.
Al-Salama ZT; Keating GM
Drugs; 2016 Dec; 76(18):1771-1778. PubMed ID: 27909994
[TBL] [Abstract][Full Text] [Related]
40. Activity of cabozantinib in radioresistant brain metastases from renal cell carcinoma: two case reports.
Négrier S; Moriceau G; Attignon V; Haddad V; Pissaloux D; Guerin N; Carrie C
J Med Case Rep; 2018 Nov; 12(1):351. PubMed ID: 30474572
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
